Intrathecal or Intraventricular Tigecycline Therapy for Central Nervous System Infection Associated with Carbapenem-Resistant Klebsiella pneumoniae

References

• Ripabelli G, Sammarco ML, Salzo A, Scutella M, Felice V, Tamburro M. New Delhi metallo-beta-lactamase (NDM-1)-producing Klebsiella pneumoniae of sequence type ST11: first identification in a hospital of central Italy. Lett Appl Microbiol. 2020;71(6):652–659. doi:10.1111/lam.13384
   Web of Science ®Google Scholar
• Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18. doi:10.1186/s12941-017-0191-3
   PubMed Web of Science ®Google Scholar
• McGill F, Heyderman RS, Panagiotou S, Tunkel AR, Solomon T. Acute bacterial meningitis in adults. Lancet. 2016;388(10063):3036–3047. doi:10.1016/S0140-6736(16)30654-7
   PubMed Web of Science ®Google Scholar
• Chiu SK, Chan MC, Huang LY, et al. Tigecycline resistance among carbapenem-resistant Klebsiella pneumoniae: clinical characteristics and expression levels of efflux pump genes. PLoS One. 2017;12(4):e0175140. doi:10.1371/journal.pone.0175140
   PubMed Web of Science ®Google Scholar
• Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11(11):834–844. doi:10.1016/S1473-3099(11)70177-3
   PubMed Web of Science ®Google Scholar
• Deng ZW, Wang J, Qiu CF, Yang Y, Shi ZH, Zhou JL. A case report of intraventricular and intrathecal tigecycline infusions for an extensively drug-resistant intracranial Acinetobacter baumannii infection. Medicine. 2019;98(15):e15139. doi:10.1097/MD.0000000000015139
   Web of Science ®Google Scholar
• Li J, Liu Y, Wu G, Wang H, Xu X. Intravenous plus intraventricular tigecycline-amikacin therapy for the treatment of carbapenem-resistant Klebsiella pneumoniae ventriculitis: a case report. Medicine. 2022;101(30):e29635. doi:10.1097/MD.0000000000029635
   PubMed Web of Science ®Google Scholar
• Humphries R, Bobenchik AM, Hindler JA, Schuetz AN. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100, 31st edition. J Clin Microbiol. 2021;59(12):e0021321. doi:10.1128/JCM.00213-21
   PubMed Web of Science ®Google Scholar
• Band VI, Satola SW, Burd EM, Farley MM, Jacob JT, Weiss DS. Carbapenem-resistant Klebsiella pneumoniae exhibiting clinically undetected colistin heteroresistance leads to treatment failure in a murine model of infection. mBio. 2018;9(2):e02448.
   PubMed Web of Science ®Google Scholar
• Hu F, Wang M, Zhu D, Wang F . CHINET efforts to control antimicrobial resistance in China. J Glob Antimicrob Resist. 2020;21:76–77. doi:10.1016/j.jgar.2020.03.007
   PubMed Web of Science ®Google Scholar
• Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30(12):1279–1291. doi:10.1592/phco.30.12.1279
   PubMed Web of Science ®Google Scholar
• Mendes CA, Cordeiro JA, Burdmann EA. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann Pharmacother. 2009;43(12):1948–1955. doi:10.1345/aph.1M277
   Web of Science ®Google Scholar
• Lindesmith LA, Baines RD Jr, Bigelow DB, Petty TL. Reversible respiratory paralysis associated with polymyxin therapy. Ann Intern Med. 1968;68(2):318–327. doi:10.7326/0003-4819-68-2-318
   Web of Science ®Google Scholar
• Wolinsky E, Hines JD. Neurotoxic and nephrotoxic effects of colistin in patients with renal disease. N Engl J Med. 1962;266(15):759–762. doi:10.1056/NEJM196204122661505
   PubMed Web of Science ®Google Scholar
• Zheng G, Cao L, Che Z, Mao E, Chen E, He J. Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review. BMC Pharmacol Toxicol. 2018;19(1):41. doi:10.1186/s40360-018-0226-1
   PubMed Web of Science ®Google Scholar
• Dai C, Li J, Li J. New insight in colistin induced neurotoxicity with the mitochondrial dysfunction in mice central nervous tissues. Exp Toxicol Pathol. 2013;65(6):941–948. doi:10.1016/j.etp.2013.01.008
   PubMedGoogle Scholar
• Dai C, Ciccotosto GD, Cappai R, et al. Curcumin attenuates colistin-induced neurotoxicity in N2a cells via anti-inflammatory activity, suppression of oxidative stress, and apoptosis. Mol Neurobiol. 2018;55(1):421–434. doi:10.1007/s12035-016-0276-6
   PubMed Web of Science ®Google Scholar
• Kaewpoowat Q, Ostrosky-Zeichner L. Tigecycline: a critical safety review. Expert Opin Drug Saf. 2015;14(2):335–342. doi:10.1517/14740338.2015.997206
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;31(2). doi:10.1128/CMR.00079-17
   Web of Science ®Google Scholar
• Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56(3):470–480. doi:10.1093/jac/dki248
   PubMed Web of Science ®Google Scholar
• Tattevin P, Solomon T, Brouwer MC. Understanding central nervous system efficacy of antimicrobials. Intensive Care Med. 2019;45(1):93–96. doi:10.1007/s00134-018-5270-1
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6):1221–1229. doi:10.1093/jac/dkl403
   PubMed Web of Science ®Google Scholar
• Lengerke C, Haap M, Mayer F, et al. Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges. Antimicrob Agents Chemother. 2011;55(1):449–450. doi:10.1128/AAC.00635-10
   PubMed Web of Science ®Google Scholar
• Wu Y, Chen K, Zhao J, Wang Q, Zhou J. Intraventricular administration of tigecycline for the treatment of multidrug-resistant bacterial meningitis after craniotomy: a case report. J Chemother. 2018;30(1):49–52. doi:10.1080/1120009X.2017.1338846
   PubMed Web of Science ®Google Scholar
• Sahin A, Dalgic N. Intraventricular plus intravenous tigecycline for the treatment of daptomycin nonsusceptible vancomycin-resistant enterococci in an infant with ventriculoperitoneal shunt infection. World Neurosurg. 2019;130:470–473. doi:10.1016/j.wneu.2019.07.045
   Web of Science ®Google Scholar
• Wang L, Zhang J, Yu X, et al. Intrathecal injection of tigecycline in treatment of multidrug-resistant Acinetobacter baumannii meningitis: a case report. Eur J Hosp Pharm. 2017;24(3):182–184. doi:10.1136/ejhpharm-2016-000972
   Google Scholar
• Long W, Yuan J, Liu J, et al. Multidrug resistant brain abscess due to Acinetobacter baumannii ventriculitis cleared by intraventricular and intravenous tigecycline therapy: a case report and review of literature. Front Neurol. 2018;9:518. doi:10.3389/fneur.2018.00518
   Web of Science ®Google Scholar
• Fang YQ, Zhan RC, Jia W, Zhang BQ, Wang JJ. A case report of intraventricular tigecycline therapy for intracranial infection with extremely drug resistant Acinetobacter baumannii. Medicine. 2017;96(31):e7703. doi:10.1097/MD.0000000000007703
   Web of Science ®Google Scholar
• Lauretti L, D’Alessandris QG, Fantoni M, et al. First reported case of intraventricular tigecycline for meningitis from extremely drug-resistant Acinetobacter baumannii. J Neurosurg. 2017;127(2):370–373. doi:10.3171/2016.6.JNS16352
   PubMed Web of Science ®Google Scholar
• Curebal B, Dalgic N, Bayraktar B. Intraventricular tigecycline for the treatment of shunt infection: a case in pediatrics. J Neurosurg Pediatr. 2018;23(2):247–250. doi:10.3171/2018.9.PEDS18470
   PubMed Web of Science ®Google Scholar
• Zhong L, Shi XZ, Su L, Liu ZF. Sequential intraventricular injection of tigecycline and polymyxin B in the treatment of intracranial Acinetobacter baumannii infection after trauma: a case report and review of the literature. Mil Med Res. 2020;7(1):23. doi:10.1186/s40779-020-00253-9
   Web of Science ®Google Scholar
• Abdallah M, Alsaleh H, Baradwan A, et al. Intraventricular tigecycline as a last resort therapy in a patient with difficult-to-treat healthcare-associated Acinetobacter baumannii ventriculitis: a case report. SN Compr Clin Med. 2020;2(9):1683–1687. doi:10.1007/s42399-020-00433-7
   Google Scholar
• Li W, Li DD, Yin B, Lin DD, Sheng HS, Zhang N. Successful treatment of pyogenic ventriculitis caused by extensively drug-resistant Acinetobacter baumannii with multi-route tigecycline: a case report. World J Clin Cases. 2021;9(3):651–658. doi:10.12998/wjcc.v9.i3.651
   Web of Science ®Google Scholar
• Liu Y, Pu Z, Zhao M. Case report of successful treatment of extensively drug-resistant Acinetobacter baumannii ventriculitis with intravenous plus intraventricular tigecycline. Antimicrob Agents Chemother. 2018;62(11). doi:10.1128/AAC.01625-18
   Web of Science ®Google Scholar
• Wang H, Zhou Q, Huang K, Yang X, Wen L. Intraventricular plus systemic antibiotic therapy for treating polymyxin-resistant Klebsiella pneumoniae ventriculitis: a case report. Open Forum Infect Dis. 2022;9(4):ofac084. doi:10.1093/ofid/ofac084
   Web of Science ®Google Scholar
• Li Z, An Y, Li L, Yi H. Intrathecal injection of tigecycline and polymyxin B in the treatment of extensively drug-resistant intracranial Acinetobacter baumannii infection: a case report and review of the literature. Infect Drug Resist. 2022;15:1411–1423. doi:10.2147/IDR.S354460
   Web of Science ®Google Scholar
• Huang G, Lai W, Wu D, Huang Q, Zhong Q, Ye X. Two cases report of intrathecal tigecycline therapy for intracranial infection with Acinetobacter baumannii and review of literatures. Infect Drug Resist. 2022;15:2211–2217. doi:10.2147/IDR.S357087
   Web of Science ®Google Scholar